

Amendments to the Specification

Please amend the paragraph at page 40, lines 1-6, as follows:

Phosphorothioate ODN (Table 1) were synthesized or obtained from a commercial source. Specifically, CpG 7909 (SEQ ID NO: 200) and CpG 10103 are both K type ODN that were obtained from Coley Pharmaceuticals (Wellesley, MA). All synthesized ODN had less than <0.1 EU of endotoxin per mg of ODN as assessed by a Limulus amebocyte lysate assay (QCL-1000, BioWhittaker).

Please amend the paragraph on page 46, lines 17-25 as follows:

Additional studies were performed using two K type ODNs, ODN 7909 (SEQ ID NO: 200) and ODN 10103. For these studies, five groups of 5 male and female rhesus macaques/group were immunized subcutaneously (SQ) or intramuscularly (IM) on study days 0 and 42 with 0.5 mL of AVA plus 0 or 250 µg of CpG ODN. All animals were monitored daily by veterinarians. Treatments were administered under appropriate anesthesia. A baseline blood sample was collected from each non-human primate (NHP) 10 days before the first injection (study day -10). Blood was collected from each NHP on days 1, 4, 11, 16, 21, 28, 35, 42, 49, 56, and 63 after the first injection.

Please substitute the attached Sequence Listing for the Sequence Listing submitted in the Preliminary Amendment dated April 29, 2005 for this application.